| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2020: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2019: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease of aged adults characterized by impaired hematopoiesis and predisposition to acute myeloid leukemia. By utilizing our infection stress-induced Tet2-deficient MDS model, we will understand the mechanism of how hematopoietic stem cells promote the initiation and propagation of MDS due to stem cells heterogeneity in epigenetic changes and impaired homeostasis in hematopoietic and non-hematopoietic tissues upon the insults of infection stresses. Lastly, we will clarify the molecular mechanism of pathogenesis of MDS and give a rationale for novel therapeutic strategy for the prevention of and eradication of MDS cells.
|
